Breadcrumbs

Gynaecological - oncology

Cervical

Endometrial

Gestational trophoblastic disease

Ovarian

Vulval

Cervical

Protocol Administration at chemotherapy unit level Review date
Cervical advanced cARBOplatin, PACLitaxel and bevacizumab Medium March 2021
Cervical advanced ciSplatin, PACLitaxel and bevacizumab Medium March 2021
Cervical locally advanced squamous cell carcinoma cISplatin chemoradiation Medium 3 March 2020
Cervical recurrent or metastatic cARBOplatin and PACLItaxel Medium March 2020

Endometrial

Protocol Administration at chemotherapy unit level Review date
Endometrial adjuvant ciSplatin chemoradiation (part 1)
The SA Health Cancer Drug Committee has endorsed the use of ciSplatin 40mg/m2 weekly as an alternative dose schedule for patients unable to tolerate the 50mg/m2 3-weekly dose.
Medium 3 September 2022
Endometrial adjuvant cARBOplatin and PACLitaxel (part 2) Medium September 2022
Endometrial recurrent medroxyprogesterone acetate Low March 2021
Endometrial recurrent or metastatic AP (DOXOrubicin cISplatin) Medium March 2021
Endometrial recurrent or metastatic cARBOplatin and PACLItaxel Medium September 2022
Soft tissue sarcoma metastatic DOCEtaxel and gemcitabine Medium June 2022

Gestational trophoblastic disease

Protocol Administration at chemotherapy unit level Review date
Gestational trophoblastic disease high risk EMA-CO (etoposide methotrexate daCTINomycin (actinomycin D) CYCLOPHOSPHamide vinCRISTine) High March 2020
Gestational trophoblastic disease high risk EP-EMA (etoposide ciSplatin etoposide methotrexate daCTINomycin)
High September 2021
Gestational trophoblastic disease low risk methotrexate Low September 2020
Gestational trophoblastic disease very high risk EP (etoposide and ciSplatin) High March 2021

Ovarian

Protocol Administration at chemotherapy unit level Review date
Ovarian advanced cARBOplatin and DOCEtaxel Medium March 2021
Ovarian advanced cARBOplatin and PACLItaxel three weekly Medium September 2022
Ovarian advanced cARBOplatin and PACLItaxel weekly Medium March 2020
Ovarian advanced cARBOplatin three weekly and PACLItaxel weekly
Medium December 2021
Ovarian advanced cARBOplatin PACLItaxel and bevacizumab Medium September 2020
Ovarian advanced combined intravenous and intraperitoneal cISplatin and PACLItaxel High March 2021
Ovarian advanced primary treatment cARBOplatin Medium September 2022
Ovarian dysgerminoma advanced or metastatic BEP (bleomycin etoposide cISplatin) Medium March 2020
Ovarian high risk stage 1 adjuvant cARBOplatin and PACLItaxel Medium September 2020
Ovarian recurrent cARBOplatin Medium March 2021
Ovarian recurrent cARBOplatin and DOXOrubicin pegylated liposomal Medium June 2022
Ovarian recurrent cARBOplatin and gemcitabine (day 1 cARBOplatin) Medium Day 1 - Low Day 8 September 2022
Ovarian recurrent gemcitabine Low September 2020
Ovarian recurrent olaparib (tablet) Low September 2022
Ovarian recurrent PACLItaxel weekly Medium March 2021
Ovarian recurrent pegylated liposomal DOXOrubicin Medium June 2022
Ovarian recurrent topotecan (modified) three weekly Medium March 2020

Vulval

Protocol Administration at chemotherapy unit level Review date
Vulval advanced cISplatin chemoradiation Medium 3 September 2020

  1. Permitted to be administered in low-risk units for second and subsequent cycles for patients with ECOG performance status 0 or 1 showing ≤ Grade 1 toxicity
  2. Fluorouracil pumps may be connected/disconnected at low-risk units
  3. Local radiotherapy services required
  4. Non-formulary drug included in the protocol
  5. Continuation dual treatment with pertuzumab and trastuzumab can be provided to appropriate patients at low-risk chemotherapy units.

^ Back to top